In preclinical studies, GnRH derivatives have been used as targeting carriers in peptide-based drug delivery platforms, enhancing the selective delivery of payloads into cancer cells via GnRHR-mediated endocytosis [34,38,39,40,41]. This evidence concerns the gene GNRH1 and cancer.